№ lp_1_2_30589
File format: docx
Character count: 2879
File size: 31 KB
The document provides a detailed form for submitting abstracts and disclosing potential conflicts of interest for participants in the "Hypertension Research International Session" at JSH2025, including information about authors, affiliations, and financial disclosures.
Year:
2025
Region / City:
Japan
Topic:
Hypertension Research
Document Type:
Form
Institution / Organization:
Japanese Society of Hypertension
Author:
Not specified
Target Audience:
Researchers and medical professionals
Period of Action:
2025
Approval Date:
Not specified
Date of Changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2024
Regulatory authority:
Therapeutic Goods Administration (TGA)
Medicine:
MACITENTAN 10 mg with TADALAFIL 40 mg (Opsynvi®)
Indication:
Pulmonary arterial hypertension (PAH), WHO Group 1, functional class II and III
Therapy type:
Dual or triple combination therapy
Dosage form:
Tablet, fixed dose combination (FDC)
Prescriber type:
Medical practitioners
Restriction type:
Authority Required (Written, Complex Authority Required)
Clinical criteria:
Treatment as dual therapy (MAC+TAD) or triple therapy with prostanoid
Population:
Adult patients with stable PAH on separate doses of macitentan and tadalafil
Previous considerations:
PBAC recommendations for macitentan and tadalafil since 2011–2014
Approval date:
16 September 2024
Source documents:
TGA registration, PBAC meeting minutes, ACM minutes August 2024, FDA, EMA, CDA references
Year:
2021
Region / city:
Australian Capital Territory
Topic:
Hypertension, Pregnancy, Maternity Care
Document Type:
Guideline
Author:
Canberra Health Services
Target Audience:
Medical officers, Registered Midwives, Nurses, Allied Health professionals, Students working under supervision
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
Not specified
Topic:
Postpartum hypertension, clinical trials, remote monitoring
Document Type:
Research Article
Organization / Institution:
Not specified
Authors:
Adi Hirshberg, Katheryne Downes, Sindhu Srinivas
Target Audience:
Researchers, healthcare professionals
Period of validity:
Not specified
Approval Date:
Not specified
Date of changes:
Not specified
Note:
Year
Topic:
Clinical trial, Idiopathic Intracranial Hypertension (IIH), vision preservation
Document type:
Participant Information Sheet
Organization / institution:
University of Birmingham
Target audience:
Adults with Idiopathic Intracranial Hypertension (IIH)
Year:
2023
Region / City:
England
Theme:
Healthcare / Clinical Coding
Document Type:
Technical Specification
Organization / Institution:
NHS England
Author:
General Practice Specification and Extraction Service (GPSES), NHS England
Target Audience:
GPES users, GP system suppliers
Effective Period:
2023/2024/2425
Approval Date:
01/04/2023
Amendment Date:
01/04/2024
Note:
Year
Topic:
Endocrine hypertension, primary aldosteronism
Document type:
Position statement
Organization / institution:
European Society of Hypertension, Japan Endocrine Society, Taiwan Society of Aldosteronism
Author:
Paolo Mulatero, Leonardo Sechi, Tracy Ann Williams, Jacques W.M. Lenders, Martin Reincke, Fumitoshi Satoh, Andrzej Januszewicz, Mitsuhide Naruse, Michael Doumas, Franco Veglio, Vin Cent Wu, Jiri Widimsky
Target audience:
Healthcare professionals, researchers in endocrinology and hypertension
Year:
2010-2024
Region / city:
Asia-Pacific
Subject:
Hepatology
Document Type:
Clinical Practice Guidelines
Organization / Institution:
Asian Pacific Association for the Study of the Liver (APASL)
Author:
APASL
Target Audience:
Healthcare professionals
Period of validity:
2010-2024
Date of approval:
2010
Date of revisions:
2024
Context:
Collection of clinical practice guidelines and consensus statements issued by the Asian Pacific Association for the Study of the Liver on various hepatological conditions, including hepatocellular carcinoma, hepatitis B and C, liver transplantation, and metabolic diseases.
Year:
2021
Region / City:
Bangalore, India
Topic:
Medical case report, Dengue in pregnancy
Document type:
Case Report
Institution:
Manipal Hospitals, Bangalore, India
Author:
Dr. Supriya Preman T P, Dr. Nirmal Sheshagiri
Target Audience:
Healthcare professionals, Obstetricians, Intensive care specialists
Period of validity:
N/A
Approval date:
N/A
Date of changes:
N/A
Note:
Contextual description
Year:
2023
Region / city:
Livingstone, Zambia; Lusaka, Zambia; Twickenham, London, UK; Nashville, TN, USA
Subject:
Hypertension, dietary salt, inflammation
Document type:
Research study
Organization / institution:
Mulungushi University, University of Zambia, St. Mary’s University, Vanderbilt University Medical Center
Author:
Sepiso K. Masenga, Leta Pilic, Benson M. Hamooya, Selestine Nzala, Geoffrey Kwenda, Douglas C. Heimburger, Wilbroad Mutale, John R. Koethe, Annet Kirabo, Sody M. Munsaka
Target audience:
Researchers, healthcare professionals
Period of validity:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2023
Region / city:
United States
Topic:
Hypertension management
Document type:
News report
Organization:
OSF HealthCare
Author:
Not specified
Target audience:
General public
Date of approval:
Not specified
Date of changes:
Not specified
Year:
2026
Region / City:
Baghdad
Topic:
Pharmacology, Hypertension
Document Type:
Educational material
Institution:
College of Dentistry, Baghdad University
Author:
Dr. Zainab Ghalib
Target Audience:
Medical students, healthcare professionals
Period of validity:
Ongoing
Approval Date:
2026-02-23
Date of Changes:
Not specified
Description:
This document provides an overview of hypertension, its classification, pathophysiology, and pharmacological treatments, with a focus on antihypertensive agents and their mechanisms of action.
Year:
2021–2023
Country:
United States
Topic:
Hypertension control and cardiovascular risk
Type of document:
Health news article
Organization:
OSF HealthCare
Author / Speaker:
Jason Trager, DO
Data source:
National Health and Nutrition Examination Survey (NHANES)
Medical field:
Cardiology
Key subjects:
Blood pressure guidelines, lifestyle modification, medication adherence, cardiovascular prevention
Referenced period:
National Heart Month
Geographic focus:
Bloomington, Illinois
Clinical thresholds discussed:
130/80 mm Hg and 140/90 mm Hg
Preventive measures mentioned:
Smoking cessation, DASH diet, exercise, weight loss, sleep apnea treatment, coronary artery calcium scan
Year:
2002
Region / City:
Kathmandu, Nepal
Topic:
Health, Hypertension, Patient Perception, Treatment Adherence
Document Type:
Research Instrument
Organization:
Not specified
Author:
Not specified
Target Audience:
Patients with Hypertension
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2023
Region / city:
Athens, Greece; Milan, Italy
Topic:
Beta-blockers, hypertension
Document type:
Meta-analysis, Scientific research article
Organization / institution:
Department of Cardiology, Helena Venizelou Hospital, Evangelismos General Hospital of Athens, University Milano-Bicocca, Policlinico di Monza
Author:
Costas Thomopoulos, George Bazoukis, Costas Tsioufis, Giuseppe Mancia
Target audience:
Medical professionals, researchers in cardiology and pharmacology
Period of validity:
N/A
Approval date:
N/A
Modification date:
N/A
Year:
2019
Region / Country:
Australia
Subject:
Pulmonary arterial hypertension medicines and subsidy policy
Document Type:
Policy review agenda item and briefing
Institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Program:
Pharmaceutical Benefits Scheme (PBS)
Topic:
Post-Market Review (PMR) of PAH medicines
Medicines Mentioned:
bosentan, ambrisentan, macitentan, sildenafil, tadalafil, iloprost, riociguat, epoprostenol
Medical Classification Referenced:
WHO Functional Class II–IV pulmonary arterial hypertension
Guidelines Referenced:
2015 European Society of Cardiology / European Respiratory Society Guidelines for the diagnosis and treatment of pulmonary hypertension
Stakeholders:
PAH Reference Group, medicine sponsors including Actelion, GlaxoSmithKline, and Pfizer
Regulatory Focus:
Revision of PBS prescribing restrictions and subsidy conditions
Key Policy Changes Considered:
Extension of subsidised monotherapy to WHO Functional Class II patients, updated PAH definition, inclusion of additional WHO Group 1 PAH subtypes, removal of calcium channel blocker trial requirement, strengthened diagnostic role of right heart catheterisation
Consultation Process:
Pre-PBAC consultation with sponsors and reference group
Associated Meetings:
PBAC meetings in November 2018, March 2019, and planned July 2019 review discussion
Related Policy Activity:
Planned stakeholder meeting on PAH combination therapy scheduled for May 2019
Note:
Year
Note:
Year
Document Type:
Deed
Year:
Not applicable
Region / City:
Not applicable
Subject:
Research ethics and manuscript submission
Document Type:
Submission Template
Organization / Institution:
Not applicable
Author:
Not applicable
Target Audience:
Researchers, Authors submitting manuscripts
Period of validity:
Not applicable
Approval Date:
Not applicable
Date of Changes:
Not applicable
Year:
2022
Region / City:
Addis Ababa, Ethiopia
Topic:
Environmental and Social Management Framework
Document Type:
Report
Author:
Ministry of Finance
Target Audience:
Government bodies, development organizations, stakeholders involved in project implementation
Period of Effectiveness:
Not specified
Approval Date:
August 2022
Amendment Date:
Not specified
Description:
This document is a framework for managing environmental and social impacts of the 3R-4-CACE project in conflict-affected communities in Ethiopia, outlining policy, legal frameworks, risks, and mitigation measures.
Year:
2020
Region / City:
Ukraine, Kyiv
Topic:
Nature-based solutions, urban development, climate change adaptation
Document Type:
Project report
Organization:
UNDP Ukraine
Author:
UNDP Ukraine
Target Audience:
Local authorities, national policymakers, NGOs, community groups, environmental stakeholders
Period of Implementation:
2019-2022
Approval Date:
November 2019
Amendment Date:
Not specified